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The aim of this study was to develop and validate a method for evaluating the release and skin permeation 
from transdermal nicotine patches using the vertical diffusion cell (VDC). The VDC is an experimental 
apparatus employed in research, development, and the pharmaceutical field because it can simulate 
conditions closest to those established in clinical trials. Two transdermal nicotine delivery systems 
marketed in Brazil to release 14 mg over 24 hours were evaluated. Release studies were carried out 
using a regenerated cellulose dialysis membrane and permeation studies were carried out using excised 
porcine ear skin. The results indicated that nicotine release from both evaluated patches follows Higuchi’s 
release kinetics, while skin permeation studies indicated zero-order release kinetics. Nicotine release 
rates were different between both evaluated patches, but drug permeation rates were not significantly 
different. According to validation studies, the method was appropriate for evaluating in vitro performance 
of nicotine patches. The proposed method can be applied to in vitro comparative studies between different 
commercial nicotine patches and may be used as an auxiliary tool in the design of new transdermal 
nicotine delivery systems.
Uniterms: Nicotine/release and skin permeation. Transdermal delivery patches/evaluation. Vertical 
diffusion cell. Skin permeation. Transdermal formulations/ nicotine delivery systems.
O objetivo deste trabalho foi o desenvolvimento e a validação de metodologia empregando a célula de 
difusão vertical para avaliação da liberação e permeação cutânea in vitro de nicotina a partir de adesivos 
transdérmicos. A célula de difusão vertical é considerada um aparato experimental importante em pesquisa 
e desenvolvimento e pode simular condições in vitro próximas aquelas observadas em ensaios clínicos. 
Neste trabalho foram avaliados dois dispositivos transdérmicos comercializados no Brasil para liberação 
controlada de 14 mg de nicotina em um período de 24 horas. Realizaram-se ensaios de liberação, usando 
membranas de diálise de celulose regenerada, e estudos de permeação cutânea, usando pele de orelha 
de porcos. Os resultados indicaram que a liberação da nicotina em ambos os dispositivos transdérmicos 
avaliados seguiu a cinética de Higuchi, enquanto que a permeação cutânea seguiu cinética de ordem 
zero. As velocidades de liberação foram diferentes para os dispositivos comerciais avaliados, entretanto 
não foram encontradas diferenças significativas para as velocidades de permeação cutânea. Conforme 
os estudos de validação, a metodologia mostrou-se apropriada para a avaliação in vitro da liberação 
e permeação cutânea a partir de adesivos transdérmicos de nicotina. O método proposto foi aplicado 
em estudos comparativos in vitro entre adesivos transdérmicos comerciais contendo nicotina. Deste 
modo, o método também pôde ser considerado como ferramenta útil que poderia ser aplicada durante o 
desenvolvimento de novas formulações transdérmicas para liberação de nicotina.
Unitermos: Nicotina/liberação e permeação cutânea. Adesivos transdérmicos/avaliação. Célula de difusão 
vertical. Permeação cutânea. Formulações transdérmicas/liberação de nicotina.
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INTRODUCTION
The transdermal route appears to have surpassed 
oral treatment as the most successful innovative research 
area in drug delivery (Barry, 2001). Numerous drugs have 
been delivered successfully through transdermal delivery 
systems (TDS), including scopolamine, nitroglycerin, 
nicotine, clonidine, fentanyl, estradiol, testosterone, 
oxybutynin, and, recently, methylphenidate, selegiline, 
rivastigmine, and rotigotine (Farahmand, Maibach, 2009).
In vitro performance methods that are biologically 
relevant have been examined to assure the quality of TDS 
and as a tool in the design of new patches. Ideal conditions 
for in vitro evaluations of TDS have been those that predict 
meaningful differences affecting the bioavailability of drugs 
(Azarmi, Roa, Lobenberg, 2007).
Methods for measuring dissolution/release of a 
drug from transdermal formulations have been described 
in important pharmacopeias. However, the dissolution 
apparatus often requires soaking the sample in an aqueous 
medium that may interact with polymeric constituents 
of patches and modify their release characteristics. The 
conditions in such tests clearly differ markedly from clinical 
situations when the TDS remains attached to the skin 
surface, with traditional formulations undergoing changes 
due to exposure to the atmosphere and skin secretions, and 
specific excipients may enter into the horny layer, facilitating 
penetration of active ingredients (Lewis et al., 2007).
Nicotine is considered to be a model molecule for 
the transdermal route (Barry, 2001). The drug is a tertiary 
amine that is soluble in water and lipids (logKow = 1.17) 
with a molecular weight of 162.23. The chemical structure 
of nicotine contains two ionizable groups: a pyridine 
and a pirrolidone ring with pKa values of 3.04 and 7.84, 
respectively. It is a colorless to pale yellow liquid that turns 
brown upon exposure to air (Nair et al., 1997; Pongjanyakul, 
Suksri, 2010).
In the early 1990s, the FDA approved four different 
nicotine TDS as adjuvants in smoking cessation. Drug 
plasmatic levels can be safely assured using these 
commercial devices for approximately 16 to 24 hours to 
provide relief of symptoms related to nicotine abstinence 
(Gore, Chien, 1998).
Various procedures have been recommended in 
United States Pharmacopeia for the evaluation of nicotine 
patches, including paddle over disc (Apparatus 5), rotating 
cylinders (Apparatus 6), and reciprocating holders 
(Apparatus 7) (United States Pharmacopeia 35, 2012). 
These pharmacopoeial assays employ a large medium 
volume without considering the skin barrier. Lewis et al. 
(1997) evaluated three commercial nicotine TDS using 
a pharmacopeial apparatus. The amount of drug released 
was independent of the medium composition and of the 
apparatus, suggesting a low discriminative power of 
these methodologies (Lewis et al., 2007). Thus, VDC is 
considered to be an important experimental apparatus that 
can simulate conditions closest to those found in clinical 
trials (Ng et al., 2010).
VDC is a modification of classical Franz diffusion 
cells. The experimental apparatus has two chambers (donor 
and receptor) separated by a highly permeable membrane 
or excised skin. Test formulation is directly applied to the 
donor chamber and the drug diffuses from the formulation 
across the support membrane to achieve the receptor phase. 
Samples can be withdrawn at different times and analyzed 
using an appropriated instrumental technique (Moser et al., 
2001; Hanson, 2010).
In this study, we propose the development and 
validation of a method for evaluating the release and skin 
permeation from nicotine patches using VDC. Two different 
patches available in the Brazilian market were evaluated 
(rate-controlling membrane and polymeric matrix). Release 
studies were carried out using regenerated cellulose dialysis 
membranes and skin permeation studies were carried out 
across excised porcine ear skin. Nicotine retention in the 
skin layers was measured after the recommended time of 
application. Drug quantification was performed using high-
performance liquid chromatography-ultraviolet radiation 
(HPLC-UV). Kinetic studies were carried out to compare 
the in vitro performance of the evaluated patches.
MATERIAL AND METHODS
Chemical and reagents
All reagents used were of analytical grade. Sodium 
hydroxide, disodium hydrogen phosphate (KH2PO4), 
sodium dihydrogen phosphate (Na2HPO4), sodium 
chloride, potassium chloride, phosphoric acid, and 
triethylamine were purchased from Vetec (Rio de Janeiro, 
Brazil). (-)-Nicotine (≥ 99%, liquid) and (-)-cotinine 
(≥ 98%) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Methanol and acetonitrile for liquid 
chromatography were acquired from Sigma-Aldrich. 
HPLC grade water was prepared by Milli-Q reverse 
osmosis (Millipore, Billerica, MA, USA) and met USP 
35 requirements (2012). 
Solutions
The receptor phase (phosphate buffer) was composed 
of 1.732 g of Na2HPO4 and 1.0 g of KH2PO4. Salts were 
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dissolved in 1000 mL of water. The isotonic receptor 
phase was used in skin permeation studies. To prepare the 
isotonic solution, 8.0 g of sodium chloride and 0.2 g of 
potassium chloride were added for each liter of receptor 
phase. The pH of the receptor phase was adjusted to 7.4 
with 85% phosphoric acid or 5 N sodium hydroxide 
solution if necessary. 
Stock standard solutions of nicotine (1.0 and 
10.0 mg mL-1) were prepared in methanol.
Nicotine patches
Two transdermal nicotine patches available in the 
Brazilian market were purchased from a local drugstore 
and evaluated in this study, including a rate-controlling 
membrane device (P1, 15 cm2 of patch size containing 
78 mg of drug) and a polymeric matrix device (P2, 20 cm2 
of patch size containing 35 mg of drug). Both commercial 
devices claimed to release 14 mg over 24 hours. These 
patches are indicated for use in the second stage of nicotine 
replacement therapy.
Patches were cut in order to reduce the surface area 
so that they could be applied to the donor compartment of 
the VDC. Devices were cut into circularly shape pieces 
of equal size (approximately 1.8 cm2, equivalent to the 
effective diffusion area of VDC). The claimed doses of 
nicotine released over the 24 hour period in trimmed 
patches were 1.7 mg cm-2 and 1.3 mg cm-2 for P1 and P2, 
respectively. The edges of the patches were immediately 
sealed with impermeable silicone glue to ensure device 
integrity and prevent lateral nicotine leakage. 
Release studies
In vitro release studies were performed in VDC 
(Hanson Research Corporation, Chatsworth, CA, 
USA). Each diffusion cell (effective diffusion area of 
1.77 cm2) was filled with 7 mL of the receptor phase 
previously de-aerated in an ultrasonic bath (Unique, 
Brazil) for 60 minutes in order to avoid bubble formation. 
The receptor phase was stirred at a constant speed of 
100 rpm. Temperature was adjusted to 32 ± 0.1 °C using 
a circulating water bath. Trimmed patches were directly 
placed over regenerated cellulose dialyses membranes 
(molecular weight cut-off 12,000 to 14,000 Da, Spectra/
Por®, Spectrum Labs, Rancho Dominquez, CA, USA) on 
the donor chamber. Membranes were previously washed 
with water in order to remove storage residues. Aliquots 
(one milliliter) were withdrawn at different time points (0, 
3, 6, 9, 12, and 24 h) and were immediately replaced with 
an equal volume of the receptor phase. 
Skin permeation studies
Skin permeation studies were performed using 
excised porcine ear skin. Whole skin was excised after 
slaughter of animals in a local slaughterhouse. Nerves, 
blood vessels, hairs, and the adipose tissue layer were 
removed with the aid of a surgical scalpel and scissors. 
Excised porcine ear skin was frozen and stored at -6 °C for 
up to one month. Excised skin samples without superficial 
damage were placed on the donor chamber of the VDC 
(Hanson Research Corporation). Trimmed patches were 
directly applied to excised skin. Each diffusion cell 
(effective diffusion area of 1.77 cm2) had been filled with 
7 mL of isotonic receptor phase de-aerated in an ultrasonic 
bath for 60 min. The receptor phase was stirred at a 
constant speed of 100 rpm. Temperature was adjusted to 
32 ± 0.1 °C using a circulating water bath. Aliquots (one 
milliliter) were withdrawn at different time points (0, 1, 
3, 6, 9, 12, and 24 h) and were immediately replaced with 
an equal volume of isotonic receptor phase. 
Nicotine extraction from porcine ear skin
After permeation studies (24 h), whole skin fragments 
were removed, briefly washed with water, and placed in 
polyethylene tubes. Skin homogenates were prepared by 
triturating whole skin fragments with 10 mL of receptor 
phase. Acetonitrile (one milliliter) was added to each 
sample tube for protein precipitation. Skin homogenates 
were centrifuged at 1500 ×g for 15 minutes and an aliquot 
of supernatant was withdrawn for nicotine analysis.
Kinetic evaluation of commercial patches
Results were plotted as the mean cumulative amount 
of drug released/permeated per unit of surface area against 
time. Different kinetic models were evaluated: 
Zero-order model (concentration against time):
Qt = Q0 + K0 t;
Higuchi’s model (concentration against square root 
of time):
Qt/Q0 = KH t1/2,
First order model (logarithm of the concentration 
against time): 
log Qt = log Q0 + K1 t
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where Qt is the amount diffused (mg) at time t (h), Q0 is 
the initial amount in the donor compartment (µg). K0 is the 
zero-order constant (µg h-1), KH is the first order constant 
(µg h-1), and K1 is the Higuchi’s constant (µg h1/2). The 
correlation coefficient (r) for each kinetic model was 
calculated to determine the best fit model.
HPLC analysis
All samples were analyzed using an auto-sampler 
HPLC on a Shimadzu (Kyoto, Japan) series LC-10A 
and a SPD-10AVP dual absorbance detector set at 
260 nm and a SPD-M10AVP diode array detector at 
200-370 nm. A Phenomenex (Torrance, CA, USA) C-18 
reverse-phase Acqua end-capping 125 Å, 5 µm column 
(150×4.6 mm) with a reverse-phase Acqua 5 µm guard 
column (15×3.2 mm) was used. The mobile phase 
consisted of phosphate buffer (20 mM) containing 0.2% of 
triethylamine: acetonitrile (8:2). The final pH was adjusted 
to 6.9 with phosphoric acid. The flow rate was 1 mL min-1. 
The injection volume was 50 µL, the run time was 7 min, 
and the retention time was approximately 4 minutes. 
All samples were filtered using a 0.45-µm syringe filter 
composed of modified hydrophilic PTFE into silanized 
HPLC vials prior to injection.
Validation studies
Validation studies were carried out in order to 
verify that the method was appropriate for release and 
skin permeation studies. Validation parameters evaluated 
included selectivity, linearity and range, accuracy and 
precision, limit of quantification (LOQ), nicotine recovery 
from porcine ear skin, and drug stability in receptor phase. 
Validation studies were performed according to ICH 
guidelines (2005).
Selectivity
Selectivity was evaluated by analyzing the receptor 
phase withdrawn in release and skin permeation studies 
without nicotine. Standard solutions of nicotine (150 µg 
mL-1) were prepared in the same experimental conditions 
and analyzed. Peak purity was investigated using 
spectral analysis with a diode array detector (Shimadzu). 
Chromatographic separation of nicotine and its major 
metabolite, cotinine, was also performed.
Linearity/range
Linearity was assessed using standard solutions 
prepared for a broad range of concentrations in the 
receptor phase. Nicotine solutions at concentrations of 
0.5, 5, 10, 50, 100, 150, and 300 µg mL-1 were analyzed. 
These studies were performed in triplicate. Linearity was 
evaluated by linear regression analysis using a weight 
factor of 1/x2. Acceptance criterion was a correlation 
coefficient of 0.999 or greater and a relative standard 
deviation (RSD) less than 2.0% for each concentration 
level. 
Accuracy and precision of analytical procedure 
Solutions were prepared at three concentrations 
levels (0.5, 50, and 300 µg mL-1) and analyzed over three 
consecutive days. Repeatability (intraday precision) 
and intermediate precision (interday precision) were 
determined using the RSD of six preparations. These 
solutions were also used in order for determining the 
accuracy of the method. Accuracy was determined as 
percentage of nicotine observed in receptor phase spiked 
with known amounts of drug.
Precision of VDC method
The precision of the VDC method was evaluated 
during release and permeation studies of Brazilian 
reference product (P1). These studies were performed in 
triplicate on two different days. Data were analyzed at 
three time points (6, 12, and 24 h). Repeatability (intraday 
precision) and intermediate precision (interday precision) 
were determined using RSD.
LOQ
LOQ was experimentally established as the lower 
concentration that showed accuracy and precision during 
the validation studies.
Drug recovery from skin samples
Nicotine was recovered from porcine ear skin 
spiked with known amounts of drug. Aliquots of standard 
solution of nicotine prepared in acetone (1.0 mg mL-1) 
were applied to excised skin (approximately 1.8 cm2). 
Three concentration levels (0.1, 0.3, and 0.6 mg cm-2) 
were spiked in skin samples. These studies were performed 
in triplicate. Skin samples were placed in polyethylene 
tubes and allowed to stand for 1 hour to ensure nicotine 
penetration. Drug extraction was carried out as previously 
described. Blank solutions of skin homogenates without 
nicotine were prepared. Standard solutions of nicotine in 
the receptor phase were prepared to determine the matrix 
effects from excised porcine ear skin.
Nicotine stability in receptor phase
Drug stability in receptor phase was evaluated at 
different time points (0, 24, 48, 72, and 96 h). Standard 
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solutions of nicotine were protected from direct light 
exposure. This study was performed in triplicate. 
All results within 98–102% of the initial values were 
considered to have no drug degradation.
Statistical analysis
Results are expressed as the mean ± standard 
deviation (SD). Statistical differences were determined 
using Student’s t-test with the level of significance set at 
P < 0.05.
RESULTS AND DISCUSSION
Method validation
Drug analysis in receptor phase was performed 
using HPLC-UV to prevent interference from skin 
contaminants. However, chromatographic analysis of 
nicotine has been reported to show some analytical 
l imitat ions (Carlisle,  Chicoine,  Wygant,  1992; 
Tambwekar, Kakariya, Garg, 2003). Nicotine is an 
alkaline drug that can interact with residual silanol 
groups, leading to secondary retention and increasing 
the tailing factor. Moreover, nicotine shows hydrophilic 
characteristics and has a low molecular weight, leading 
to a reduced retention factor in reversed-phase columns 
(McCalley, 1999). In this study, we analyzed two 
strategies described in literature for nicotine analysis 
by HPLC: the addition of ion pairing reagents and the 
addition of competitive amines (Carlisle, Chicoine, 
Wygant, 1992). Sodium dodecyl sulfate was utilized as 
an ion pair reagent. Some disadvantages were observed 
in using this strategy. The analyses were more time-
consuming due to column stabilization and the cost 
of ion pairing reagents for liquid chromatography 
with appropriated purity grade was high. For these 
reasons, using competitive amines in the mobile phase 
is preferable as a rapid, simple, and efficient method for 
chromatography assays of nicotine. The conditions used 
were previously described. According to the ICH, system 
suitability results are considered to be an integral part of 
validation protocols. The system suitability results are 
shown in Table I (ICH, 2005).
According to selectivity studies, interfering peaks 
at the nicotine retention time during the analysis were not 
observed. Chromatograms of nicotine samples extracted 
from ear porcine skin and its respective blank are shown 
in Figure 1.
Peak purity was determined by spectral overlap 
of the standard solution of nicotine in receptor phase 
and nicotine samples extracted from ear porcine skin. A 
satisfactory similarity index of 0.999217 was found. The 
purity based on the chromatographic peaks in performance 
studies using commercial patches was also ensured. 
Chromatographic separation of nicotine and its major 
metabolite cotinine was performed at a resolution of 2.5. 
The retention factor (k′) for cotinine was 1.9.
A broad linear range was selected to directly 
measure nicotine in the samples during performance 
studies, but data heterogeneity must also be evaluated 
when broad linear ranges are selected. The leak observed 
for homoscedastic data may have resulted from the large 
deviations present at large concentrations that generally 
influence (weight) the regression line more than smaller 
deviations associated with smaller concentrations. Thus, 
accuracy at the lower end of the range was impaired. The 
use of weighted least squares linear regression is a simple 
and effective method for counteracting this situation 
(Almeida, 2002).
Homoscedasticity was tested using the F-test 
(Almeida, 2002). The results indicated a significant 
difference between variances. Thus, a weighting 
factor 1/x2 was adopted for the linearity assay. The 
calibration equation and correlation coefficient (r) were 
y = 47854.33x + 11000.88 and 0.999769, respectively. 
Therefore, drug response was linear at a concentration 
range of 0.5-300.0 µg mL-1. 
LOQ was experimentally determined as the lower 
concentration of range (0.5 µg mL-1). The value was 
established according to the results of accuracy and 
precision tests and is shown in Table II.
The accuracy and precision results of the analytical 
method were considered satisfactory and are shown in 
Table II.
Precision results from in vitro performance studies in 
VDC are shown in Table III. For these studies, the criteria 
adopted were an RSD less than 15.0% due to biological 
variation in skin permeation studies.
The stability assay demonstrated that nicotine 
was stable in the receptor phase for 96 hours (Table IV). 
TABLE I - System suitability results according to USP 35 (2012), 
n = 6
Parameters Mean SD
Retention factor (k′) 2.4 0.02
Tailing factor 1.3 0.19
Theorical plate number (N) 3249 238
Retention time (min) 4.3 0.02
SD, standard deviation
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Measuring stability is important for ensuring that no drug 
degradation has occurred during in vitro assays prior to 
HPLC analysis.
Recoveries of known amounts of nicotine from skin 
were performed (Table V). The results demonstrated that 
high percentages of nicotine can be recovered from skin 
samples.
Evaluation of nicotine patches
In vitro performance studies are an important tool 
for characterizing nicotine patches. Release studies can 
ensure batch-to-batch consistency and detect manufacturing 
deviations during routine quality control. Skin permeation 
studies are important in research and development for 
FIGURE 1 - Chromatograms of blank (A) and nicotine (B) extracted from excised skin samples (retention time of nicotine was 
approximately 4 minutes)
TABLE II - Precision and accuracy of analytical method
Concentration (µg mL-1)
Precision (RSD, n = 6) Accuracy (%, n = 6)
Intraday Interday Intraday Interday
0.5 2.7 7.9 100.5 97.0
51.0 1.6 2.2 99.6 101.9
306.0 2.1 1.6 100.2 100.2
RSD, relative standard deviation
TABLE III - Precision of in vitro performance studies
Time (h)
Precision of release studies (RSD, n = 6) Precision of skin permeation studies (RSD, n = 6)
Intraday Interday Intraday Interday
6 0.3 9.1 3.5 8.7
12 10.3 9.5 2.8 3.5
24 9.6 11.3 2.8 2.3
RSD, relative standard deviation
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TABLE IV - Stability of nicotine in receptor phase (n = 3)
Initial 
solution 24 h 48 h 72 h 96 h
Mean % 100.00 100.65 100.58 101.55 101.56
RSD 1.69 1.68 1.76 1.48 1.47
RSD, relative standard deviation
TABLE V - Recovery of nicotine from skin samples (n = 3)
Concentration (mg cm-2) Recovery (%, n = 3) ± RSD
0.1 95.6 ± 1.8
0.3 97.7 ± 0.2
0.6 97.3 ± 0.1
RSD, relative standard deviation
predicting in vivo behavior of transdermal and topic 
formulations with respect to the skin barrier (Olivier, 
Rabouan, Couet, 2003; Azarmi, Roa, Lobenberg, 2007). 
In general, differences are expected between release and 
permeation rates. In this study, release and permeation 
studies were conducted using VDC and results were used 
to compare the in vitro performance of commercial devices. 
In vitro release profiles of two different patches 
are presented in Figure 2. After 24 hours, the amount of 
nicotine released from P1 and P2 were 846.3 ± 11.3 µg 
cm-2 and 1033.3 ± 97.7 µg cm-2, respectively; these values 
were significantly different (P < 0.05). Regarding the 
percentage of claimed drug release, P2 released 145.4% at 
24 hours while P1 released 90.7% at this same time. Due 
to the different design of the patches, the largest amounts 
released by P2 were associated with polymeric matrix 
dissolution. Despite the use of a dialysis membrane to 
FIGURE 2 - Release profiles from nicotine commercial patches P1 (■) and P2 (●) using the VDC method, n = 6. Results are 
expressed as the cumulative amount of drug released (A) and the cumulative % of dose released (B).
decrease direct contact between the patch and the receptor 
phase, the aqueous medium remained highly permeable 
through the dialysis membrane and its contact with patch 
matrix increased. In P1, the rate-controlling membrane 
from the formulation prevented device dissolution; 
consequently, released amounts were low compared to the 
claimed release amount.
For any TDS, the initial concentration gradient 
between the drug reservoir and skin should be sufficiently 
high to ensure the required drug flux over the recommended 
time of application. These considerations imply that the 
amount of drug in the patches is generally much larger 
than the amount of released drug (Lewis et al., 1997; 
Barry, 2001). P2 contains a low drug load compared to 
P1. According to our release studies, P2 released 58.1% of 
its total nicotine load at 24 hours, while P1 released only 
16.3% of its total nicotine load by the same time point.
The results of permeation studies are presented in 
Figure 3. After 24 hours, the permeated amounts from P1 
and P2 were 992.5 ± 22.4 µg cm-2 and 892.9 ± 96.0 µg cm-2, 
respectively. Results were significantly different (P<0.05) 
despite their similar values. Permeation amounts were 
closer or slightly higher than the claimed release dose. 
The results were 106.3% and 127.6% for P1 and P2, 
respectively.
The most relevant animal model for human skin 
is the pig. Porcine skin has histological and biochemical 
properties that have repeatedly been shown to be similar 
to human skin. Porcine ear skin is particularly well-suited 
for permeation studies and gives comparable results to 
human skin. However, porcine ear skin was shown to be 
more permeable than human skin in some cases (Godin, 
Touitou, 2007). Thus, extrapolation of the results must be 
carefully performed.
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According to Kalia and Guy (2001), the property 
of a patch to control drug release can be measured using 
the fractional rate control (Fd). Fd is the ratio between 
the amount of drug permeating through the skin barrier 
and the amount of drug released from the TDS into 
an aqueous sink system. Thus, an Fd = 1 implies that 
delivery is controlled entirely by the device; however, 
when Fd<1, the skin is also contributing to the controlled 
release. Results for Fd were 1.17 and 0.88 for P1 and P2, 
respectively.
Nicotine is a highly permeable drug and the total 
drug amount delivered must be rapidly permeated across 
the skin. Thus, it can be expected that the skin barrier has 
a limited influence on drug permeation rate. For patch 
P2, the amount of drug permeated was low compared 
to the amount of drug released. This suggests that the 
contact between the formulation and the receptor phase 
decreased at the skin barrier, leading to minor swelling of 
the polymeric matrix in permeation studies. In this manner, 
Fd indicates that approximately 88% of the release rate of 
P2 was controlled by formulation. Compared to P1, the 
amount of drug permeated was higher than the amount of 
drug released, giving an Fd value of greater than 1. These 
results suggest that the rate-controlling membrane patch 
regulates the release rate throughout its extension, while 
the skin has a minor effect in total drug flux. It is important 
to note that the value of Fd evaluates only the amounts of 
drug released and permeated in a given period of time and 
it must be considered that the skin barrier has a significant 
effect on release kinetic.
The effect of trimming the edges of the nicotine 
patch before application in the Franz-type cell has been 
discussed in previous studies (Lewis et al., 1997; Olivier, 
Rabouan, Couet, 2003). Lateral diffusion of nicotine 
can occur in the device edges that are not in contact 
with the effective area of diffusion. This can lead to an 
overestimation of the results. According to Olivier and 
et al. (2003), reducing the surface area of the device 
leads to a reduction of the cumulative amounts of drug 
permeated through the skin and, consequently, decreased 
permeation rates (Olivier, Rabouan, Couet, 2003). In 
this study, we trimmed nicotine patch to a size as close 
as possible to the effective diffusion area in order to 
prevent lateral diffusion of the drug/formulation and to 
assure patch integrity.
Nicotine retention in the skin
Nicotine can be retained in the skin despite its 
high permeability. At steady state, the concentration of 
nicotine in the skin layers is expected to be maintained in 
a stationary state. The results of nicotine retained within 
skin layers are presented in Table VI.
The retained amounts did not significantly differ 
between the two commercial patches (P=0.055). These 
results indicate that the difference between release/
permeation was not related to drug retention within skin. 
Furthermore, it is important to note that drug retention was 
due to the possibility of accumulation of nicotine within 
FIGURE 3 - In vitro skin permeation profiles from commercial nicotine patches P1 (■) and P2 (●) using the VDC method, n = 6. 
Results are expressed as cumulative amount of drug that permeated through the skin (A) and the cumulative % of dose permeated (B).
TABLE VI - Amounts of nicotine retained within skin after 24 h 
of skin permeation studies, n = 6
Evaluated patch Concentration ± SD (mg cm-2)
P1 0.362 ± 0.038
P2 0.320 ± 0.029
SD, standard deviation
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skin layers, resulting in the release of residual amounts of 
nicotine after removing the patches (Benowitz, Hukannen, 
Jacob III, 2009).
Kinetic studies
Kinetic evaluations were carried out using data 
obtained in the performance studies. Results are presented 
in Table VII.
Both devices showed Higuchi’s release kinetics 
during release studies. P1 showed a nicotine flux of 163.6 
± 13.4 µg cm-2 h-1/2, whereas the release of P2 showed a 
greater drug flux of 207.1 ± 42.2 µg cm-2 h-1/2. These values 
were significantly different (P < 0.05).
Zero-order or Higuchi’s release profiles can be 
expected for TDS with rate-controlling membranes, as 
was observed for P1. In this design, the drug remains 
stored in a reservoir that is enclosed on one side with 
an impermeable backing. These patches also contain an 
adhesive layer that avoids direct contact between the semi-
permeable membrane and the horny layer. In this case, 
zero-order kinetics can be expected. However, nicotine 
can accumulate in the adhesive layer during storage, 
leading to a Higuchi’s release profile in practice. For TDS 
with a polymeric matrix, such as for P2, drug is dispersed 
into a polymeric material, simplifying the manufacturing 
process. Matrix systems may have only three layers 
without a semi-permeable membrane or just two layers by 
incorporating the drug directly into a polymeric adhesive 
matrix. Matrix release profiles are expressed as Higuchi’s 
model, which is characterized by passive diffusion from 
the polymeric matrix (Gore, Chien, 1998).
Although the release profile for both patches fit 
better to Higuchi´s model, data obtained from permeation 
studies showed a better fit to the zero-order model (linear 
versus time). Permeation rates of P1 and P2 were 41.7 ± 
1.2 µg cm-2 h-1 and 38.3 ± 3.6 µg cm-2 h-1, respectively. 
The results were not significantly different (P = 0.068). 
This demonstrates that permeated amounts of P1 were 
larger than the values of the amounts of drug released 
(Fd >1), with the skin having an important effect on 
drug kinetics.
CONCLUSION
The VDC method was validated and applied to 
characterize the release and permeation kinetics from 
nicotine TDS. We demonstrated that in vitro performance 
of commercial devices with different designs (rate-
controlling membrane or polymeric matrix) can be 
evaluated using VDC. The release rate of nicotine from 
TDS was influenced by the formulation and the skin 
barrier. Both devices showed release profiles following 
Higuchi release kinetics and permeation profiles 
following the zero-order model, likely due to skin barrier. 
This method showed appropriate results for kinetic 
evaluations of nicotine patches; however, predicted plasma 
concentrations in humans is necessary for establishing an 
in vivo-in vitro correlation. Although the VDC method 
generally simulates in vivo conditions, it should be 
carefully evaluated whether the amounts determined in 
vitro are associated with the amounts released by the 
device during in vivo clinical trials. Thus, this method 
was found to be appropriate for comparative studies 
between different transdermal nicotine patches and may 
be a useful tool for designing new transdermal nicotine 
delivery systems.
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